Literature DB >> 8520495

The incidence and epidemiology of plasma cell neoplasms.

D Bergsagel1.   

Abstract

Plasma cell neoplasia includes monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), and Waldenström's macroglobulinemia (WM). In MGUS, a large, stable clone does not cause symptoms; additional change(s) is/are required to convert this clone into a progressively expanding tumor that becomes symptomatic, as in MM or WM. The prevalence of MGUS (i.e., the number of cases in a defined population at a certain time) is 20 times greater than MM. The incidence (i.e., the number of cases developing in a defined population in a defined period) has not been determined for MGUS. Between 1960 and 1969, the average, annual, age-adjusted (1950 standard) incidence of MM in Malmö, Sweden was 3.4/10(5). The incidence of MM is strongly influenced by the age and race of the population, and the diagnostic services available. MM is a disease of old age; it rarely occurs before the age of 40. The incidence of MM increases rapidly with age, is lowest among the Chinese and Japanese, intermediate among Caucasians in America and Europe, and highest among blacks in the USA. The striking differences in the incidence of MM in different countries appears to be due to racial rather than environmental differences, since the low incidence among the Chinese and Japanese in Asia has migrated with them to the Bay area of California and to Hawaii. The high incidence of MM in USA black males (10.8/10(5)) and females (7.2/10(5)) is more than twice the rate for whites in the same regions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520495

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  11 in total

1.  Socioeconomic status and multiple myeloma among US blacks and whites.

Authors:  D Baris; L M Brown; D T Silverman; R Hayes; R N Hoover; G M Swanson; M Dosemeci; A G Schwartz; J M Liff; J B Schoenberg; L M Pottern; J Lubin; R S Greenberg; J F Fraumeni
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

2.  Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daiichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Authors:  Joseph P Ritchie; Vishnu C Ramani; Yongsheng Ren; Annamaria Naggi; Giangiacomo Torri; Benito Casu; Sergio Penco; Claudio Pisano; Paolo Carminati; Monica Tortoreto; Franco Zunino; Israel Vlodavsky; Ralph D Sanderson; Yang Yang
Journal:  Clin Cancer Res       Date:  2011-01-21       Impact factor: 12.531

4.  The role of serum protein electrophoresis in the detection of multiple myeloma: an experience of a corporate hospital.

Authors:  Sunita Tripathy
Journal:  J Clin Diagn Res       Date:  2012-11

5.  Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.

Authors:  DeannaLee M Beauvais; Oisun Jung; Yang Yang; Ralph D Sanderson; Alan C Rapraeger
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

Review 6.  Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Authors:  Ralph D Sanderson; Yang Yang
Journal:  Clin Exp Metastasis       Date:  2007-11-20       Impact factor: 5.150

7.  IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia.

Authors:  Saman Hewamana; Chris Pepper; Steve Couzens; Alun Thomas; Steven Knapper
Journal:  Int J Hematol       Date:  2008-10-11       Impact factor: 2.490

8.  Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Authors:  Heinz Ludwig; Brian G M Durie; Vanessa Bolejack; Ingemar Turesson; Robert A Kyle; Joan Blade; Rafael Fonseca; Meletios Dimopoulos; Kazuyuki Shimizu; Jesus San Miguel; Jan Westin; Jean-Luc Harousseau; Meral Beksac; Mario Boccadoro; Antonio Palumbo; Bart Barlogie; Chaim Shustik; Michele Cavo; Philip R Greipp; Douglas Joshua; Michel Attal; Pieter Sonneveld; John Crowley
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

9.  Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.

Authors:  O Jung; V Trapp-Stamborski; A Purushothaman; H Jin; H Wang; R D Sanderson; A C Rapraeger
Journal:  Oncogenesis       Date:  2016-02-29       Impact factor: 7.485

10.  More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.

Authors:  Jin Lu; Jing Lu; Wenming Chen; Jing Wang; Yuliang Huo; Jian Hou; Xiaojun Huang
Journal:  Drug Des Devel Ther       Date:  2016-11-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.